首页> 外文期刊>Journal of drugs in dermatology: JDD >Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne
【24h】

Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne

机译:进行了随机,对照,评估者盲目的研究,以比较3种非处方痤疮方案在轻度或中度痤疮患者中的功效和耐受性

获取原文
获取原文并翻译 | 示例

摘要

Background: Acne vulgaris is a common dermatologic disease that most frequently affects adolescents and young adults. Over-thecounter (OTC) acne treatment regimens are increasingly being used by individuals with acne. Objectives: To compare the efficacy, user satisfaction, and tolerability of the OTC regimens MaxClarity TM, ProactivR, and MuradR in the treatment of mild and moderate acne. Methods: Two randomized, evaluator-blinded, split-face studies were conducted, each involving 20 subjects with acne, to evaluate MaxClarity against Proactiv (study 401) and MaxClarity against Murad (study 404) over 8 weeks. Results: Clinically and statistically significant reductions in acne lesion counts were achieved at 8 weeks compared with baseline for each regimen using MaxClarity, Proactiv, and Murad. Similar reductions in lesion counts and improvements in Investigator's Static Global Assessment grades were observed between MaxClarity and either Proactiv or Murad, in the respective studies. MaxClarity was well tolerated, with no treatment-related adverse events observed in any treatment group and no discontinuations due to adverse events. Overall, most subjects were satisfied with all study treatments. Conclusions: MaxClarity is an effective alternative to either Proactiv or Murad for use in the treatment of mild and moderate acne.
机译:背景:寻常痤疮是一种常见的皮肤病,最常见于青少年和年轻人。痤疮患者越来越多地使用非处方(OTC)痤疮治疗方案。目的:比较OTC方案MaxClarity TM,ProactivR和MuradR在轻度和中度痤疮治疗中的功效,用户满意度和耐受性。方法:进行了两项随机,评估者盲目,双面部研究,每项研究均涉及20名痤疮受试者,以评估在8周内针对Proactiv的MaxClarity(研究401)和针对Murad的MaxClarity(研究404)。结果:与使用MaxClarity,Proactiv和Murad的每种方案的基线相比,与基线相比,在8周时痤疮病变计数的临床和统计学显着降低。在各自的研究中,在MaxClarity与Proactiv或Murad之间观察到了类似的病灶计数减少和研究者的静态整体评估等级改善。 MaxClarity具有良好的耐受性,在任何治疗组中均未观察到与治疗相关的不良事件,也没有因不良事件而停药。总体而言,大多数受试者对所有研究治疗均感到满意。结论:MaxClarity是用于治疗轻度和中度痤疮的Proactiv或Murad的有效替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号